News and Updates

Extracorporeal Blood Filter Removes Circulating Tumor Cells: Dialysis-like Cell Removal Therapy to be Studied for Treating Metastatic Cancer

Sep 20, 2022

ExThera Medical’s CEO Bob Ward Receives Prestigious BioMedSA Award for Innovation in Healthcare and Bioscience Including a Groundbreaking Device to Treat COVID-19

Sep 13, 2022

ExThera Medical Wins a Gold Edison Award for COVID-19 Innovations: Therapeutic Impact for the Seraph® 100 Blood Filter

May 10, 2022

Results Published for Seraph 100 Treatment of COVID-19 Confirm Survival Benefit Signal

Apr 21, 2022

PURIFY Investigators Announce First Patient Enrolled in a US Randomized Controlled IDE Trial Evaluating Seraph 100 for the Treatment of Septic Shock

Mar 2, 2022

ExThera Medical & Fresenius Medical Care Sign Distribution Agreement for Seraph 100 Blood Purification Device in Mexico

Feb 3, 2022

Patient Enrollment is Complete in the DOD-Funded Study of Extracorporeal Hemopurification of Critically Ill COVID-19 Patients

Jan 18, 2022

Treatment for critically ill COVID patients results in significant improvement in survival rate according to new study

Jan 11, 2022

ExThera Medical and Asahi Kasei Medical Enter into Partnership to Expand Reach of Treatment for the Critically Ill

Dec 21, 2021

ExThera and Asahi Kasei Medical secure exclusive distribution agreement in Japan

ExThera Medical Partners with Predicate Healthcare Performance Group to Expand Reach of Proven COVID-19 Treatment

Dec 9, 2021

Treatment for Critically Ill COVID Patients Begins 1st Randomized Clinical Trial

Sep 1, 2021

Canadian Health Authority Grants ExThera’s Seraph 100 Blood Filter an Interim Order for Treatment of COVID-19

Aug 9, 2021

ExThera Expands Distribution of Blood Purification and Pathogen Reduction Treatment for Sepsis and COVID-19 in Europe – ExThera Medical and Fresenius Medical Care to offer Seraph 100 Microbind Affinity Filter in Turkey, Finland, and Estonia

Jul 28, 2021

BioMedSA Announces ExThera’s CEO as the Winner of the 2021 Innovation Award in Healthcare and Bioscience

Jul 9, 2021

Clinical Trial for Groundbreaking Device to Treat Septic Shock set to Begin

Jun 14, 2021

Blood Purification and Pathogen Reduction Treatment for Sepsis and COVID-19 Set for Pan-European Distribution Launch

May 26, 2021

Seraph 100 Blood Filter Shows Substantially Improved Survival Rates for COVID-19 Patients

Apr 26, 2021

Lakhmir Chawla, MD, of Silver Creek Pharmaceuticals, Joins ExThera Medical Board of Directors

Mar 23, 2021

Fresenius Medical Care expands critical care offering with ExThera Medical’s Seraph 100 adsorber

Jan 7, 2021

Michael Porter of Harvard Business School has Joined the Board of Directors of ExThera Medical Corporation

Sep 29, 2020

Seraph® 100 Blood Filter Used by U.S. Department of Defense to Treat COVID-19

Aug 11, 2020

DOD to Fund a Multi-Center Randomized Clinical Trial of COVID-19 Treatment with ExThera’s Seraph 100 Blood Filter

Jun 9, 2020

US FDA Grants ExThera’s Seraph-100 Blood Filter Emergency Use Authorization for the Treatment of COVID-19 After Promising Results in Europe and the USA

Apr 17, 2020

ExThera’s Affinity Blood Filter Is Used to Treat COVID-19 Patients

Mar 26, 2020

ExThera Medical Commences Commercial EU Sales of the Seraph® 100 Blood Filter, a Treatment for Drug-Resistant Bloodstream Infections

Jan 10, 2020

ExThera Medical Receives CE Mark Approval for the Seraph® 100 Blood Filter: “A Promising Treatment for Drug-resistant Bloodstream Infections and Sepsis”

Aug 6, 2019

Dr. Stefan Büttner to Present Clinical Trial Results of ExThera’s Seraph® Pathogen-removing Filter at International Symposium on Intensive Care and Emergency Medicine

Mar 18, 2019

ExThera Medical Creates Scientific Advisory Board to Advance the Organization’s Global Clinical Trial Program

Mar 11, 2019

ExThera Medical Elects Preston and Dollarhyde to its Board of Directors to Drive the Organization’s Next Phase of Innovation and Growth

Jan 7, 2019